Compare CLNE & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | IVVD |
|---|---|---|
| Founded | 2001 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.3M | 437.1M |
| IPO Year | 2006 | 2021 |
| Metric | CLNE | IVVD |
|---|---|---|
| Price | $1.73 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.32 | ★ $8.75 |
| AVG Volume (30 Days) | 1.3M | ★ 5.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $341,599,000.00 | $53,426,000.00 |
| Revenue This Year | $1.13 | $61.57 |
| Revenue Next Year | $22.65 | $41.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $1.72 | $0.49 |
| 52 Week High | $3.11 | $3.07 |
| Indicator | CLNE | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 26.38 | 39.75 |
| Support Level | N/A | $0.73 |
| Resistance Level | $2.40 | $1.25 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 14.52 | 44.34 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.